Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

India Globalization Capital Inc (IGC)

India Globalization Capital Inc (IGC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 33,779
  • Shares Outstanding, K 63,734
  • Annual Sales, $ 910 K
  • Annual Income, $ -11,510 K
  • 60-Month Beta 1.71
  • Price/Sales 24.43
  • Price/Cash Flow N/A
  • Price/Book 4.05
Trade IGC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.26
  • Most Recent Earnings $-0.09 on 02/14/24
  • Latest Earnings Date 02/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 555.40% ( +163.82%)
  • Historical Volatility 122.55%
  • IV Percentile 52%
  • IV Rank 32.69%
  • IV High 1,358.65% on 09/20/23
  • IV Low 165.38% on 12/14/23
  • Put/Call Vol Ratio 0.01
  • Today's Volume 125
  • Volume Avg (30-Day) 341
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 5,630
  • Open Int (30-Day) 2,713

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/15
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +1,665,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3101 +40.28%
on 03/20/24
0.9099 -52.19%
on 04/04/24
+0.1099 (+33.80%)
since 03/12/24
3-Month
0.2651 +64.09%
on 01/24/24
0.9099 -52.19%
on 04/04/24
+0.1694 (+63.78%)
since 01/12/24
52-Week
0.2501 +73.93%
on 12/20/23
0.9099 -52.19%
on 04/04/24
+0.1050 (+31.82%)
since 04/12/23

Most Recent Stories

More News
IGC Pharma (NYSE American: IGC) Announces Results of Annual Meeting

IGC Pharma (NYSE American: IGC) has announced that during its annual meeting of stockholders scheduled for and convened on Aug. 18, 2023, (the “annual meeting”), all proposals as disclosed on the Definitive...

IGC : 0.4401 (-16.96%)
IGC Pharma Inc. (NYSE American: IGC) Releases Q1 2024 Financial Report

IGC Pharma (NYSE American: IGC), a company that develops advanced cannabinoid-based formulations for treating diseases and conditions, including but not limited to Alzheimer’s disease, period cramps...

IGC : 0.4401 (-16.96%)
IGC Pharma (NYSE American: IGC) Announces Participation in Planet MicroCap Showcase

IGC Pharma (NYSE American: IGC) will be presenting at this month’s Planet MicroCap Showcase: VEGAS 2023; the event is slated for Wednesday, April 26, 2023, at 7:30 p.m. ET. According to the announcement,...

IGC : 0.4401 (-16.96%)
IGC Pharma to Attend Investor Summit

Potomac, Maryland--(Newsfile Corp. - March 22, 2023) - IGC Pharma, Inc. (NYSE American: IGC) ("IGC" or the "Company") today announced that Ram Mukunda, Chief Executive Officer, and Claudia Grimaldi, Principle...

IGC : 0.4401 (-16.96%)
India Globalization Capital (NYSE American: IGC) Fighting Alzheimer’s with Treatments in Study Phase

Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued...

IGC : 0.4401 (-16.96%)
India Globalization Capital (NYSE American: IGC) Leads the Way with Cannabis-Based Treatment for Alzheimer’s

In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational...

IGC : 0.4401 (-16.96%)
India Globalization Capital (NYSE American: IGC) Advances Drug Candidate in Treating Alzheimer’s

India Globalization Capital (NYSE American: IGC), in a historic first, has begun phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from...

IGC : 0.4401 (-16.96%)
India Globalization Capital (NYSE American: IGC) Set to Begin IGC-AD1 Trials at Canadian Sites

India Globalization Capital (NYSE American: IGC) today announced its receipt of a no objection letter from Health Canada for approval of its “Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled...

IGC : 0.4401 (-16.96%)
India Globalization Capital (NYSE American: IGC) Files Updated Life Sciences Presentation

India Globalization Capital (NYSE American: IGC) today announced the filing of a life sciences presentation with the SEC on Form 8K. The presentation, available on the SEC website as well as published...

IGC : 0.4401 (-16.96%)
India Globalization Capital (NYSE American: IGC) Applauds Milestone for Medical Cannabis Industry

India Globalization Capital (NYSE American: IGC) applauds the signing of the Medical Marijuana and Cannabidiol Research Expansion Act, which was signed into law by President Biden on Friday Dec. 2, 2022....

IGC : 0.4401 (-16.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

IGC Pharma Inc. develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. IGC Pharma Inc., formerly known as India Globalization Capital Inc., is based in POTOMAC, Md....

See More

Key Turning Points

3rd Resistance Point 0.5950
2nd Resistance Point 0.5740
1st Resistance Point 0.5520
Last Price 0.4401
1st Support Level 0.5090
2nd Support Level 0.4880
3rd Support Level 0.4660

See More

52-Week High 0.9099
Fibonacci 61.8% 0.6579
Fibonacci 50% 0.5800
Fibonacci 38.2% 0.5021
Last Price 0.4401
52-Week Low 0.2501

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar